American College of Cardiology

Journalists: please note that all presentations are embargoed until the time of their actual presentation at the Late-Breaking Clinical Trial (LBCT) sessions or ACC press conference, whichever comes first. The date and time of each official presentation at an LBCT session is provided at the end of each trial topic description.

Highlights from:

SUNDAY | MONDAY | TUESDAY | WEDNESDAY

SUNDAY, MARCH 6, 2005
8:30 – 9:15 am
PRESS CONFERENCE: Effective Strategies to Prevent Procedural Complications

• The Impact of Pre-Procedural Plasma C-Reactive Protein on the Neointimal Hyperplasia After Successful Coronary Artery Stenting (Session 841; Tuesday, March 8th, 10:45am)
  Myung Ho-Jeong, M.D., Chonnam National University Hospital, South Korea
  
• Efficacy and Tolerability of Oral Rapamycin to Prevent Restenosis After Coronary Stent Implantation: The Prospect, Randomized ORAR II Study (Session 839; Tuesday, March 8th, 11:00am)
  Alfredo E. Rodriguez, M.D., Columbia University Medical Center
  
• Reduction in Mortality and Other Procedural Complications Following Percutaneous Coronary Angioplasty in Patients With Hyperlipidemia is Largely Due to Statin Treatment (Session 852; Tuesday, March 8th, 2:00pm)
  Mandeep Singh, M.D., Mayo Clinic
  
• Pre-Treatment With Statins Reduces Ischemic Neurological Events in Patients Undergoing Carotid Stent Implantation (Session 878; Wednesday, March 9th, 10:30am)
  Stanislaw J. Skaluba, M.D., University of Texas Health Science Center

Moderator: Karen Smith, M.D., University of Florida
  Listen to the news conference: HIGH BAND (DSL, cable, T1) or LOW BAND (dial-up)

9:30 - 10:30 a.m.
Break for Session #22: Late Breaking Clinical Trials in Interventional Cardiology

10:30 - 11:15 a.m.
PRESS CONFERENCE: Late-Breaking Clinical Trials in Interventional Cardiology

• Paclitaxel-Eluting Stent Versus Sirolimus-Eluting Stent for the Prevention of Restenosis in Diabetic Patients With Coronary Artery Disease (Session 22-3; Sunday, March 6th, 9:30am)
  Adnan Kastrati, M.D., Deutsches Herzzentrum, Germany
  
• Eight-Month Outcome of the Reality Study: A Prospective Randomized Multi-Center Head-to-Head Comparison of the Sirolimus-Eluting Stent (Cypher) and the Paclitaxel-Eluting Stent (Taxus) (Session 22-5; Sunday, March 6th, 9:45am)
  Marie-Claude Morice, M.D., Institut Cardiovasculaire Paris Sud, France
  
• Arterial Revascularization Therapies Study Part II: Sirolimus-Eluting Stents for the Treatment of Patients With Multivessel De Novo Coronary Artery Lesions (Session 22-7; Sunday, March 6th, 10:00am)
  Patrick Serruys, M.D., Thoraxcenter, Erasmus Medical Center, Netherlands
  
• Outcomes of the Polymer-Based, Paclitaxel-Eluting Taxus Stent in Complex Lesions: Principal Clinical and Angiographic Results From the Taxus-V Pivotal Randomized Trial (Session 22-9; Sunday, March 6th, 10:15am)
  Gregg Stone, M.D., Columbia University Medical Center

Moderator: John Hirshfeld, M.D., University of Pennsylvania
  Listen to the news conference: HIGH BAND (DSL, cable, T1) or LOW BAND (dial-up)

12:00 - 1:00 p.m.
PRESS CONFERENCE: Breakthroughs in Coronary Stenting
Read the abstract

• Superior Acute and Follow-Up Results of Sirolumus-Eluting Stents Compared to Vascular Brachytherapy For In-Stent Restenosis (Session 805; Tuesday, March 8th, 4:30pm)
  Rainer Hoffmann, M.D., University Aachen, Germany
  
• First Human Absorbable Metal Stent Implantation in Coronary Arteries (Session 1058-1/1; Monday, March 7th, 12:30pm)
  Raimund Erbel, M.D., University Clinic Essen, Germany
  
• Arterial Revascularization Therapies Study Part II of the Sirolimus-eluting Stent in the Treatment of Patients With Multivessel De Novo Coronary Artery Lesions (Session 1058-6/6; Monday 7th, 12:30pm)
  Patrick Serruys, M.D., Erasmus Medical Center, Netherlands
  
• Durability of the Polymer-Based, Paclitaxel-Eluting TAXUS Stent in Key Patient Subsets: Two-Year Results from the TAXUS-IV Trial (Session 807-3; Monday, March 7th, 11:00am)
  Mary Russell, M.D., Boston Scientific
  
• Long-Term Clinical Benefit of CYPHER Sirolimus-eluting Coronary Stent: Three Year Follow-up of the SIRIUS Study (Session 807-4; Monday, March 7th, 11:15am)
  David R. Holmes, M.D., Mayo Clinic

Moderator: William O’Neill, M.D., William Beaumont Hospital, Michigan
  Listen to the news conference: HIGH BAND (DSL, cable, T1) or LOW BAND (dial-up)

1:00 - 2:00 p.m.
PRESS CONFERENCE: Assessing Heart Disease Risk in Specific Populations
Read the abstract

• Skin Cholesterol Content Identifies Subclinical Atherosclerosis in Asymptomatic Adults (Session 820; Monday, March 7th, 2:15pm)
  James H. Stein, M.D., University of Wisconsin Medical School
  
• Myocardial Perfusion Imaging Risk Stratifies Women With Intermediate or High Duke Treadmill Score (Session 809; Monday, March 7th, 11:45am)
  Justin B. Lundbye, M.D., Hartford Hospital
• Underestimation of Coronary Risk by Measuring Subclinical Coronary atherosclerosis in Referral Cohorts: Evidence From the Large Unselected Heinz Nixdorf Recall Cohort (Session 863; Tuesday, March 8th, 4:45pm)
  Axel Schmermund, M.D., University Clinic Essen, Germany
  
• Multimarker Approach Predicts Adverse Cardiovascular Events in Women Evaluated for Suspected Ischemia: A Report From the NHLBI-Sponsored WISE Study (Session 814; Monday, March 7th, 2:00pm)
  Christopher B. Arant, M.D., University of Florida
  
• Evaluation of Coronary Artery Disease (CAD) in Diabetic Patients Presenting with Dyspnea But No Chest Pain: Findings on Myocardial Perfusion Imaging (SPECT) and Coronary Angiogram (CATH) (Session 861; Tuesday, March 8th, 4:15pm)
  Su Min Chang, M.D., University of Wisconsin

Moderator: Gerald Fletcher, M.D., Mayo Clinic, FL
  Listen to the news conference: HIGH BAND (DSL, cable, T1) or LOW BAND (dial-up)

2:30 - 3:15 p.m.
PRESS CONFERENCE: Late-Breaking Clinical Trials and Trial Updates

• Pioglitazone Reduces Neoimtima Formation After Coronary Stent Implantation: A Randomized, Placebo-Controlled, Double-Blind Trial in Non-Diabetic Patients (Session 25-3; Sunday, March 6th, 4:00pm)
  Nikolaus Marx, M.D., University of Ulm, Germany
  
• Randomized Multicenter Comparison of Sirolimus Versus Bare Metal Stent Implantation in Complex Coronary Disease: The Stenting of Coronary Arteries in Non Stress/Benestent Disease (SCANDSTENT) Trial (Session 25-5; Sunday, March 6th, 4:15pm
  Henning Kelbaek, M.D., Rigshospitalet University Hospital, Denmark
  
• Randomized Study on the Effectiveness of a Filter Device for Distal Protection During Direct Percutaneous Catheter Intervention for Acute Myocardial Infarction: Results of the PROMISE (Protection Devices in PCI-Treatment of Myocardial Infarction for Salvage of Endangered Myocardium) Study (Session 25-9; Sunday, March 6th, 4:45pm)
  Michael Gick, M.D., Herzzonirum Bad Krozingon, Denmark
  
• A Randomized Trial of High Loading Dose of Clopidogrel for Reduction of Periprocedural Myocardial Infarction in Patients Undergoing Coronary Intervention: Results From the ARMYDA-2 (Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty) Study (Session 25-11; Sunday, March 6th, 5:00pm)
  Germano Di Sciascio, M.D., Campus Bio-Medico University, Italy
  
• A Randomized Comparison of the Endeavor ABT-578 Drug Eluting Stent With a Bare Metal Stent for Coronary Revascularization: Results of the Endeavor II Trial (Session 25-13; Sunday, March 6th, 5:15pm)
  William Wijns, M.D., Cardiovascular Center, Halst, Belgium

Moderator: Lloyd Klein, M.D., Rush University Medical Center
  Listen to the news conference: HIGH BAND (DSL, cable, T1) or LOW BAND (dial-up)

4:00 - 5:30 p.m.
Break for Session 25: Late-Breaking Clinical Trials and Trial Updates

MONDAY, MARCH 7, 2005

8:00 - 10:00 a.m.
Break for Presidential Plenary Session/Simon Dack Lecture (Larry King, Citation)

9:15 - 10:30 a.m.
Break for Session 404: Late-Breaking Clinical Trials I

9:30 - 10:00 a.m.
Press Availability: Larry King

10:30 - 11:15 a.m.
PRESS CONFERENCE: Late-Breaking Clinical Trials I

• Optimal Pharmacological Therapy in Implantable Cardioverter Defibrillator Patients (OPTIC) Trial (Session 404-3; Monday, March 7th, 9:15am)
  Stuart Connolly, M.D., McMaster University
  
• Safety of Parecoxib and Valdecoxib in the Treatment of Postoperative Pain Following Coronary Artery Bypass Graft Surgery or Major General Surgery (Session 404-5; Monday, March 7th, 9:15am)
  Andrew Whelton, M.D., Universal Clinical Research Center Inc
  
• The Cardiac Resynchronisation Heart Failure Study (CARE-HF). A Randomised Study of The Effects of Optimal Pharmacological Therapy Alone or Combined With Cardiac Resynchronisation in Patients with Advance Heart Failure and Cardiac Dyssynchrony (Session 404-7; Monday, March 7th, 9:15am)
  John Cleland, M.D., University of Hull, England
  
• A Randomized Trial of Vitamin E in the Primary Prevention of Cardiovascular Disease in 39,876 Women: The Women's Health Study (Session 404-9; Monday, March 7th, 9:15am)
  Julie Buring, M.D., Brigham and Women's Hospital
  
• A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women: The Women's Health Study (Session 404-11; Monday, March 7th, 9:15am)
  Paul Ridker, M.D., Brigham and Women's Hospital

Moderator: Robert Harrington, M.D., Duke Clinical Research Institute
  Listen to the news conference: HIGH BAND (DSL, cable, T1) or LOW BAND (dial-up)

12:00 - 1:00 p.m.
PRESS CONFERENCE: Effect of Statins in Fighting Heart Failure
Read the abstract

• Intensive Statin Therapy Reduces CRP in ACS Patients With Metabolic Abnormalities and Adverse Lifestyle Features. An Analysis from PROVE IT_TIMI 22 (Session 850; Tuesday, March 8th, 2:00pm)
  Christopher Cannon, M.D., Brigham and Women's Hospital
  
• Endothelial Function, Low-Density Lipoprotein Cholesterol, and Moderate and Intensive Cholesterol Lowering in Coronary Artery Disease: A REVERSAL Trial Substudy (Session 831; Tuesday, March 8th, 9:15am)
  Robert A. Vogel, M.D., University of Maryland School of Medicine
  
• Polymorphins in Lipoprotein and Lipid Metabolism Genes Predict Response to Pravastin Therapy (Session 1001; Sunday, March 8th, 12:30pm)
  Marc S. Sabatine, M.D., Brigham and Women's Hospital
  
• Statin Use is Associated With a Marked Improvement in Survival in an Advanced Heart Failure Population from the COMPANION Trial (Session 851; Tuesday, March 8th, 3:15pm)
  Andrew D. Sumner, M.D., Penn State College of Medicine

Moderator: William Boden, M.D., Hartford Hospital
  Listen to the news conference: HIGH BAND (DSL, cable, T1) or LOW BAND (dial-up)

1:00 p.m.-2:00 p.m.
PRESS CONFERENCE: Precursors and Warning Signs of CVD
Read the abstract

• Inflammation and Acute Hyperglycemia: A Double-Edged Sword in Diabetics With Non-ST Elevation ACS. Analyses from the TIMI Database (Session 832; Tuesday, March 8th, 8:45am)
  Kausik K. Ray, M.D., Brigham and Women's Hospital
  
• Population Trends in Hypertension Detection, Treatment and Control 1980-2002:The Minnesota Heart Survey (Session 842-6; Tuesday, March 8th, 11:15am)
  Russell V. Luepker, M.D., University of Minnesota
  
• Independent Components of Chronic Kidney Disease as a Cardiovascular Risk Factor: Results from the Kidney Early Evaluation Program (KEEP) (Session 842-4; Tuesday, March 8th, 10:45am)
  Peter A. McCullough, M.D., William Beaumont Hospital
  
• Infection and Inflammation are Associated With Hypertension: The GOCADAN Study (Session 842-7; Tuesday, March 8th, 11:30am)
  Jianhui Zhu, M.D., Washington Hospital Center
  
• Association of Neighborhood Socioeconomic Status With Functional Capacity and All Cause Mortality (Session 1116; Tuesday, March 8th, 12:30pm)
  Mehdi Shishehbor, M.D., Cleveland Clinic Foundation

Moderator: Clive Rosendorff, M.D., Mount Sinai School of Medicine
  Listen to the news conference: HIGH BAND (DSL, cable, T1) or LOW BAND (dial-up)

2:30 p.m.-3:00 p.m.
PRESS CONFERENCE: IHI's Campaign to Save 100,000 Lives by June 2006

• The Institute of Healthcare Improvement (IHI) will present an overview of the IHI’s Campaign to Save 100,000 lives by June 2006. The session will highlight the outstanding performing hospitals on AMI treatment, the AMI intervention based on ACC Guidelines and the IHI’s proven methods. (Sunday, March 6, 2:30 - 4:30 pm)

Moderator: John Brush, M.D., incoming Governor of Virginia and incoming Chair of the Quality Strategic Directions Committee
  Listen to the news conference: HIGH BAND (DSL, cable, T1) or LOW BAND (dial-up)

Press Conferences
TUESDAY, MARCH 8, 2005

8:30 a.m.-10:00 a.m.
Break for Tuesday Hot Topic: COX-2 Inhibitors

8:30 a.m.-10:00 a.m.
Break for Session 410: Late-Breaking Clinical Trials II

10:00 a.m.-10:30 a.m.
Press Availability: COX-2 Inhibitors Panelists

10:30 a.m.-11:15 a.m
PRESS CONFERENCE: Late-Breaking Clinical Trials II

• Effect of Lowering Low Density Lipoprotein Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease: Results of the Treating to New Targets Study (Session 410-3; Tuesday, March 8th, 8:30am)
  John LaRosa, M.D., SUNY Downstate Medical Center
  
• The Ango-Scandinavian Cardiac Outcomes Trial: Morbidity-Mortality Outcomes n the Blood Pressure-Lowering Arm of the Trial (ascot-bpla) (Session 410-5; Tuesday, March 8th, 8:30am)
  Peter Sever, M.D., Imperial College London, England
  
• The Chronicle Offers Management to Patients With Advanced Signs and Symptoms of Heart Failure (COMPASS-HF) Study: Ambulatory Acquired Hemodynamic Guided Management of Heart Failure (Session 410-7; Tuesday, March 8th, 8:30am)
  Robert Bourge, M.D., University of Alabama at Birmingham
  
• Value of Endothelin Receptor Inhibition With Tezosentan in Acute Heart Failure Studies (veritas): Two Multi-Center, Double-Blind, Placebo-Controlled, Parallel-Group Trials Assessing the Efficacy, Safety and Tolerability of Tezosentan in Acute Heart Failure (Session 410-9; Tuesday, March 8th, 8:30am)
  John McMurray, M.D., Western Infirmary, Scotland
  
• 2-Year Data From the RIO-Europe Study: Metabolic Effects of Rimonabant in Overweight/Obese Patients (Wednesday, March 9th, 8:30am)
  Luc Van Gaal, M.D., University Hospital Antwerp, Belgium

Moderator: Thomas Ryan, M.D., Boston University
  Listen to the news conference: HIGH BAND (DSL, cable, T1) or LOW BAND (dial-up)

11:15 a.m.-12:00 p.m.
PRESS CONFERENCE: Critical Analysis of Coronary Artery Bypass Surgery
Read the abstract

• Differential Impact of Coronary Artery Bypass Graft Surgery and Diabetes on Cause of Death, A Long-Term Report from the BARI Study (Session 862-3; Tuesday, March 8th, 4:00pm)
  David R. Holmes, M.D., Mayo Clinic
  
• Clinical Outcomes of Patients with Multivessel Disease Treated With Three or More Sirolimus-Eluting Stents (Session 862-4; Tuesday, March 8th, 4:15pm)
  Ron Waksman, M.D., Washington Hospital Center
  
• The Medicine Angioplasty or Surgery Study (MASS Registry): Impact of Diabetes on Long-Term Prognosis in Patients With Single or Multivessel Coronary Artery Disease. Five Years of Follow-up. (Session 862-5; Tuesday, March 8th, 4:30pm)
  Whady Hueb, M.D., Heart Institute, University of Sao Paolo, Brazil

Moderator: Fayez Shamoon, M.D., Seton Hall University
  Listen to the news conference: HIGH BAND (DSL, cable, T1) or LOW BAND (dial-up)

1:00 p.m.-2:00 p.m.
PRESS CONFERENCE: Late-Breaking Clinical Trials: Mechanisms and New Therapeutic Approaches

• Intracoronary Autologous Bone-Marrow Cell Transfer After Myocardial Infarction: A Double-Blind, Randomized, and Placebo-Controlled Clinical Trial (Session 413-3; Tuesday, March 8th, 2:00pm)
  Stefan Janssens, M.D., University of Leuven, Belgium
  
• Three Year Follow-Up of the Feasibility and Safety of Autologous Myoblast Transplantation for Ischemic Cardiomyopathy in Patients Undergoing Coronary Artery Bypass Grafting (Session 413-5; Tuesday, March 8th, 2:00pm)
  Nabil Dib, M.D., Arizona Heart Institute
  
• Myocardial Repair by Percutaneous Cell Transplantation of Autologous Skeletal Myoblast as a Stand Alone Procedure in Post Myocardial Infarction Chronic Heart Failure Patients (Session 413-7; Tuesday, March 8th, 2:00pm)
  Patrick Serruys, M.D., Erasmus Medical Centre, Netherlands
  
• Effects of PG-116800, a Matrix Metalloproteinase Inhibitor to Prevent Left Ventricular Remodeling After Acute Myocardial Infarction (Session 413-9; Tuesday, March 8th, 2:00pm)
  Douglas Weaver, M.D., Henry Ford Health System
  
• AGENT-3 Final Results (Session 413-11; Tuesday, March 8th, 2:00pm)
  Timothy Henry, M.D., Minneapolis Heart Institute
  
• A Multicenter, Randomized Trial Assessing the Value of Mechanical Reperfusion in Patients With Acute Myocardial Infarction Presenting >12 Hours From Onset of Symptoms (Session 413-13; Tuesday, March 8th, 2:00pm)
  Albert Schomig, M.D., Deutsches Herzzentrum, Germany
  
• Prospective, Randomized, and Controlled Study on Effect of Catheter Ablation for the Cure of Atrial Fibrillation Study (CACAFStudy) (Session 413-15; Tuesday, March 8th, 2:00pm)
  Emanuele Bertaglia, M.D., Mirano Hospital, Italy
  
• Continuous Positive Airway Pressure for Heart Failure Patients With Central Sleep Apnea (CANPAP) (Session 413-17; Tuesday, March 8th, 2:00pm)
  Douglas Bradley, M.D., University of Toronto
  
• Prospective Evaluation of EECP in Congestive Heart Failure: The PEECH Trial (Session 413-21; Tuesday, March 8th, 2:00pm)
  Arthur Feldman, M.D., Jefferson Medical College

Moderator: Christopher O’Connor, M.D., Duke University
  Listen to the news conference: HIGH BAND (DSL, cable, T1) or LOW BAND (dial-up)

2:00 p.m.-4:00 p.m.
Break for Session 413: Late-Breaking Clinical Trials: Mechanisms and New Therapeutic Approaches

WEDNESDAY, MARCH 9, 2005

8:30 a.m.-9:30 a.m.
Break for Session 415: Late-Breaking Clinical Trials III

9:30 a.m.-10:15 a.m.
PRESS CONFERENCE: Late-Breaking Clinical Trials III

• Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY): Thrombolysis in Myocardial Infarction (TIMI) 28 (Session 415-3; Wednesday, March 9th, 8:30am)
  Marc Sabatine, M.D., Brigham and Women's Hospital
  
• COMMIT/CCS-2: Randomised, Placebo-Controlled Trial of Adding Clopidogrel to Aspirin in 46,000 Acute Myocardial Infarction Patients (Session 415-5; Wednesday, March 9th, 8:30am)
  Zhengming Chen, M.D., University of Oxford, Clinical Trial Service Unit and Epidemiological Studies, England
  
• COMMIT/CCS-2: Placebo-Controlled Trial of Early Metoprolol in 46,000 Acute Myocardial Infarction Patients (Session 415-7; Wednesday, March 9th, 8:30am)
  Rory Collins, M.D., University of Oxford, Clinical Trial Service Unit and Epidemiological Studies, England
  
• Glucose-Insulin-Potassium Study in Patients With ST-Elevation Myocardial Infarction Without Signs of Heart Failure: The Gips-II Trial (Session 415-9; Wednesday, March 9th, 8:30am)
  Jorik Timmer, M.D., Isala Klinieken, Netherlands

Moderator: Christopher Cannon, M.D., Brigham and Women’s Hospital
  Listen to the news conference: HIGH BAND (DSL, cable, T1) or LOW BAND (dial-up)

11:00 a.m.-12:00 p.m.
PRESS CONFERENCE: Improving Quality of Care in Cardiac Patients
Read the abstract

• Impact of Evidence-Based Heart Failure Therapy Use at Hospital Discharge on Treatment Rates During Follow-Up: A Report from The Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) (Session 844-4; Tuesday, March 8th, 10:45am)
  Gregg Fonarow, M.D., UCLA Medical Center
  
• Evaluation of Computerized Quality Improvement Tool to Improve Compliance with AHA/ACC Guidelines for Management of CAD and Post-ACS Patients in an Outpatient Clinic (Session 844-5; Tuesday, March 8th, 11:00am)
  James T. Dove, M.D., Prairie Cardiovascular Consultants
  
• The Relation Between Angina, Treatment and Quality of Life in Cardiac Patients (Session 870; Tuesday, March 8th, 8:30am)
  Dr. Patricia Cowper, Ph.D., Duke University Medical Center
  
• The Risk of Bleeding Complications After Different Doses of Aspirin: A Post-Hoc Analysis of 192,036 Patients Enrolled in 31 Randomized Controlled Trials (Session 870; Wednesday, March 9th, 9:30am)
  Victor L. Serebruany, M.D., Heart Drug Research
  
• Gender Differences in the Application of Evidence-Based Therapies for Treatment of Acute Myocardial Infarction: The American College of Cardiology's Guidelines Applied in Practice (GAP) Projects in Michigan (Session 844; Tuesday, March 8th, 11:45am)
  Kim Eagle, M.D., University of Michigan Medical Center

Moderator: John Rumsfeld, M.D., Denver VAMC, University of Colorado
  Listen to the news conference: HIGH BAND (DSL, cable, T1) or LOW BAND (dial-up)